This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
In the past century, vaccinologists have attempted to mimic the pathogens in their immune-enhancing capacity and thus to
induce danger signals. This led to the development of life-saving vaccines based on live attenuated viruses and bacteria as well
as toxoids. In keeping with the same dogma of mimicking pathogens? danger signals in host cells, intense research in vaccine
adjuvant discovery has focused on toll like receptors, mutant toxins and viral and bacterial vectors. However, recent evidence
suggests that nutritive components such as vitamins and a subclass of polyphenols also possess immunomodulating properties
without the potential toxic side effects of mimicking danger signals in traditional adjuvant research. We have designed a chemically
well-defined and GMP-manufacturable Nutritive Immune-enhancing Delivery System (NIDS) composed of combination of
select vitamins, and a plant based polyphenol in various delivery systems including organic and inorganic pharmaceutically
acceptable carriers. We have generated impressive and significant enhancement of both local and systemic immune responses in
a mouse model following mucosal and systemic vaccinations with NIDS and compared the responses to vaccinations with other
licensed or in development vaccine adjuvants and delivery systems. This approach promises to open a new era in the design and
development of safe and effective vaccines.
Dr. Michael Vajdy is Co-founder, President and Chief Scientific Officer of EpitoGenesis, Inc., established in 2008. Dr. Vajdy is a mucosal immunologist
and Vaccinologist with over 20 years of direct academic and industry experience in designing mucosal and systemic adjuvants and vaccines,
studying mucosal and systemic B and T cell immune induction mechanisms and long-term immunological memory, and product development.
Following his Ph.D. Studentship at Goteborg University under the supervision of Dr. Nils Lycke, a prominent mucosal immunologist, Dr. Vajdy
completed post doctoral fellowships with Dr. Katherine Knight, then President of the American Association of Immunology and Dr. Marian Neutra, a
renowned expert in mucosal biology and M cells of the intestinal Peyer?s patches and mucosal HIV vaccine development. Dr. Vajdy was recruited
to Chiron Corporation (later Novartis Vaccines and Diagnostics, Inc.) where his work was instrumental in the development of mucosal and systemic
vaccine products against various infectious diseases. Dr. Vajdy advanced one of these products, i.e. HIV-env, to non-human primate studies in which
he demonstrated vaccine efficacy in protection against SHIV challenges. A clinical trial, based on Dr. Vajdy?s results from this macaque study was
then conducted. He remained there for 9.5 years with increasing responsibilities including project leadership for a vaccine manufacturing platform
technology. He also held simultaneous academic positions as Adjunct Clinical Assistant Professor with the Department of Internal Medicine, Division
of Infectious Diseases and Visiting Associate Professor at Department of Medical Microbiology and Immunology, University of California, Davis. He
was also a Faculty member with the graduate group, Department of Comparative Pathology, University of California, Davis. In these capacities, he
trained student/fellows and wrote collaborative NIH grants. Dr. Vajdy has authored over 50 peer reviewed manuscripts and book chapters; he is
the editor of a book entitled ?Immunity against Mucosal Pathogens? (Springer, 2008) and has been PI or Investigator on several funded NIH grants.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals